PRESS RELEASE click here: BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen
Elasmogen is progressing next generation biologics for inflammatory, autoimmune diseases and oncology
Elasmogen exploits its unique soloMER™ technology as drugs in small, simple, and stable formats that are amenable to site-specific and systemic delivery.
Elasmogen is progressing life-extending therapies for those patients that have been let down by current small molecule and systemic monoclonal antibody approaches.
